Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Efgartigimod IV for Myasthenia Gravis
Recruiting1 awardPhase 2 & 3
Charlottesville, Virginia
This trial is investigating the effects of a drug called efgartigimod in children and adolescents aged 2-18 with a condition called gMG. The trial will last up to 28 weeks for each participant, and will involve two parts: a dose-confirmatory part (8 weeks) and a treatment response-confirmatory part (18 weeks).
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.